28 October 2015 - Deborah Wilkes
Archived
Pfizer said a 7% rise in worldwide sales by its Consumer Healthcare division in the third quarter of 2015 was primarily due to the performance of Nexium 24HR in the US.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.